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ABSTRACT OF THE DISSERTATION
Existence of Inhibitor of Apoptosis in Tumor Exosomes
by
Malyn May Asuncion Valenzuela
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, March 2015
Dr. Nathan R. Wall, Chairperson
Pancreatic cancer is a deadly and aggressive disease. The only option for
metastatic pancreatic cancer is chemotherapy where only the antimetabolites gemcitabine
(Gem) and 5-fluorouracil (5FU) are used clinically. However, resistance to these
antimetabolites remains a problem highlighting the need to discover and develop new
antimetabolites that will improve a patient’s overall survival. Cancer is a disease that has
acquired numerous molecular, biochemical and cellular changes. Resistance to apoptosis
is one of the characteristics of cancer, of which the inhibitor of apoptosis (IAP) family of
proteins plays an important role. It has also been shown that cancer cells secrete vesicles
called tumor exosomes (TEX) which are loaded with bioactive molecules which strongly
influences the tumor microenvironment. Both protein and mRNA of the IAP Survivin,
cIAP1, cIAP2 and XIAP are released into the extracellular space by not only the
pancreatic cancer cell line PANC-1, but also from other cancer and non-cancer cell lines.
IAP release may play an important role in pancreatic cancer’s lack of response to
antimetabolite agents and eventual progression to chemoresistance. These findings can be
used to design and develop novel compounds that can be used in combination with Gem
or 5FU which are designed to target exosomes, in particular IAP packaging, which may
make a vital impact in the treatment for metastatic pancreatic cancer.
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CHAPTER ONE
INTRODUCTION
INHIBITOR OF APOPTOSIS (IAPS) IN TUMOR EXOSOMES

Pancreatic Cancer
Pancreatic cancer is an aggressive disease that silently attacks. Today, it is the 4th
leading cause of cancer deaths in the United States [1-3]. There are several risk factors
that lead to the development of pancreatic cancer which include lifestyle factors, such as
smoking and a diet high in fat and nitrite, diseases such as chronic pancreatitis and
diabetes, and genetic factors [4] . Symptoms, such as jaundice and back or abdominal
pain, are usually presented once the disease has progressed to the advanced stages [2].
Since there are no screening tests and patients are asymptomatic in the early stages of the
disease, pancreatic cancer is usually diagnosed in the advanced stages, affecting
approximately 85% of the patients. At the time of the diagnosis, the survival time given
to the patients is 4-8 months, where less than 1% survive more than 5 years [5-7].
Patients that have metastatic pancreatic adenocarcinoma are treated with the only firstline FDA approved treatment GEMZAR or gemcitabine (Gem) [8]. Gem is an
antimetabolite agent that is designed to inhibit replication of DNA and normal cellular
metabolic processes [9,10], which will be discussed further in the next chapter. At
present, numerous efforts are being made to improve treatment strategies for metastatic
pancreatic cancer, such as the search for new antimetabolite drugs, as well as using
combinations of therapeutic agents.
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Inhibitor of Apoptosis
Cancer is a disease that has acquired a number of molecular, biochemical and
cellular changes, which is common in most, even all types of cancer. These changes
affect normal cellular physiology, which are essential for malignant growth. The changes
include independence from growth signals, loss of sensitivity to antigrowth signals,
resistance to apoptosis, unlimited ability to replicate, angiogenesis maintenance, and
invasion of tissue and metastasis [11]. Out of these acquired capabilities of cancer cells,
we are most interested in the resistance to apoptosis. The inhibitor of apoptosis (IAP)
family of proteins is of special interest, which includes cIAP1, cIAP2, XIAP and
Survivin.
IAPs are characterized by an ~70 amino acid baculovirus IAP repeat (BIR)
domain and a RING domain in the C-terminus of each family member [12,13]. IAPs are
known to be endogenous caspase inhibitors [14]. Activated caspase-3, -7 and -9 are
inhibited by cIAP1, cIAP2 and XIAP by directly binding to the caspases using their BIR
domains [15-18]. Survivin is the smallest IAP family member and is the only IAP that
has only one BIR domain and no RING domain, making Survivin structurally unique
among the rest of the family [19]. Another unique feature of Survivin is its
multifunctional role in various cellular activities, which includes the regulation of
mitosis, protection from cell death, and adaptation to stressful environments [20,21].
Survivin is found to be localized in the cytoplasm, mitochondria and nucleus, with its
subcellular location determining its function [22,23]. It has been shown that Survivin’s
role in the regulation of mitosis is carried out by a nuclear Survivin pool [24].
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Alternatively, mitochondrial Survivin is able to suppress cell death in tumor cell lines
and plays a part in tumorigenesis in immunocompromised mice [25].

Survivin in Cancer & Treatment
Survivin expression is normally seen during the embryonic and fetal
developmental stages, but is either low in expression or absent in tissues that are
terminally differentiated. Survivin has also been shown to be present in highly
proliferative adult cells, such as thymocytes, CD34+ bone-marrow-derived stem cells, T
cells, vascular endothelial cells and gastrointestinal tract mucosa. Expression levels of
Survivin in these cells are significantly lower compared to tumor cells, where there is a
striking overexpression of this IAP in virtually every cancer type. High levels of Survivin
expression in cancer cells have been associated with dismal prognosis, disease
progression, metastatic dissemination, therapy resistance and overall dismal disease
outcome [21,26,27]. In pancreatic cancer cells, radioresistance was enhanced by
Survivin, which functioned as an inducible radioresistance factor [28]. Another study has
shown that both Survivin mRNA and protein levels were higher in Cisplatin-treated
gastric cancer cells compared to untreated cells [29]. Both these studies give indication
that Survivin plays an essential role in chemotherapy and radiotherapy resistance,
increasing the ability of cancer cells to evade apoptosis, thus providing cytoprotection to
malignant cells [30].
To date, Survivin is one of the most tumor specific transcriptome [21], and in
addition to its presence in both solid tumor and hemapoeitic malignancy, this IAP makes
an exciting target for anti-cancer treatment. There have been many efforts in recent years
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to develop novel anti-cancer therapeutics targeting Survivin to both inhibit tumor growth
as well as increase tumor cells’ sensitivity to conventional chemotherapeutic agents
[27,31]. Thus far, there are numerous strategies to target Survivin from mRNA to protein
levels. Small molecule inhibitor YM155 acts by inhibiting transcription of Survivin
mRNA, while anti-sense oligonucleotides, hammerhead ribozymes and siRNA are
designed to degrade Survivin mRNA and/or inhibit protein translation. Strategies to
inhibit Survivin at the protein level include small molecule antagonist Sheperdin, which
prevents Hsp90/Survivin interaction, as well as expression of two Survivin dominant
negative mutants Cys84Ala and T34A into tumor cells introduced by plasmid or viral
vectors [27,31].
In recent years, many studies have been done to determine whether
downregulation of Survivin could reverse chemotheray and radiotherapy resistance in
cancer cells. Several groups have shown that inhibition of Survivin expression by
shRNA, RNAi, as well as emodin, a natural compound, resensitizes a variety of cancer
cells, including squamous cell carcinoma of the tongue [30], osteosarcoma [32], breast
cancer [33], and pancreatic cancer [34,35] to cisplatin, adriamycin, and gemcitabine. All
the Survivin based therapies mentioned previously have shown to be successful in
decreasing Survivin expression levels, inhibiting further growth of malignant cells and
increasing sensitivity to chemo,- and radiotherapies.

Existence of Secreted Membrane Vesicles in Cancers
Tumors are known to shed membrane vesicles [36]. In particular, human and
mouse tumor cells have been shown to secrete tumor cell-derived
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exosomes (TEX), constitutively into the extracellular space [37]. The morphology,
density and certain membrane markers expressed, such as LAMP1, MHC class I, HSP70
and HSP80, on the released TEX are similar to the dendritic cell-derived exosomes
(DEX) [38]. Despite similarities to DEX, there are differences in the molecular profiles
and biological roles of TEXs, both of which give an indication of the cell of origin [39].
The specific protein content found on and within exosomes not only reflects their origin,
but in addition, establishes their functional role [40]. TEX secreted from neoplastic cells
express diverse tumor antigens, which signifies the type of tumor cells from where TEXs
were released [41]. In vitro, it has been shown that TEX released from breast carcinoma
cells contain HER2, while carcinoembryonic antigen (CEA) was found in the exosomes
secreted from colon carcinoma cells, and proteins MelanA/Mart-1 and gp100 that are
expressed in melanoma cells are found on the released TEX [38,42]. This phenomenon is
also evident in vivo, where plasma from cancer patients contain membrane vesicles that
are characterized by the expression of tumor antigens which reflect the tumor of origin
[43,44].
When immunocompetent and nude mice were pre-treated with murine mammary
TEX, an accelerated growth of the tumor was observed [45]. This observation led to
various studies to try to elucidate the role of secreted membrane vesicles in cancer. TEX
can be described as “multi-purpose carriers” which have important roles in the
communication, protection, as well as the exchange of genetic information with
neighboring cells [46]. The production and secretion of TEX is important for the tumor.
They serve a protective function, have a supportive role in the survival and growth of the
tumor cells, are involved in the promotion of host tissue invasion and subsequent
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metastasis, and facilitate evasion from the immune response [47,48]. Acting in a
paracrine fashion, the diverse function of TEX is speculated to be due to the various
bioactive molecules found within and on the vesicles having a strong influence on the
surrounding environment [41,43,44,49].
The promotion of angiogenesis is due in part to the upregulation of vascular
endothelial growth factor (VEGF) [50] and release of matrix metalloproteinases (MMPs)
in neighboring, even distant endothelial cells, which are brought by TEX containing
tetraspanin family members [51], epithelial growth factor receptor (EGFR) [52], plateletderived tissue factor (TF) [53] or developmental endothelial locus-1 protein [43]. TEX
has also been implicated in the further growth of tumor by the exchange of genetic
material. mRNA was detected within exosomes released from glioblastoma cells.
Neighboring microvascular endothelial cells that take up the exosomes and translate the
mRNA become liable for further tumor growth leading to the stimulation of angiogenesis
[50]. In addition, tissue invasion and stromal remodeling can be facilitated by proteases
and MMP transport and release via exosomes [54,55]. Recent studies have shown that
TEX provide a protective role to the cancer cells, which can be manifested in different
ways. Survivin, a member of the inhibitor of apoptosis (IAP) protein family, was found to
be released from tumor cells via exosomes [56]. The protective role of TEX can be
attained by the accumulation and packaging of chemotherapeutic drugs or its metabolites
into the vesicles, thus decreasing cellular levels of the drug, a factor leading to drug
resistance [57,58]. This phenomenon has been observed in various cancer cells. Cisplatin
enhanced the shedding of the vesicle from melanoma cells [5], while doxorubicin was
found in the exosomes released from ovarian carcinoma cells [58]. Despite the beneficial
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roles of TEX for the tumor cells and the tumor microenvironment, TEX can be a useful
tool for detecting the malignant condition. Serum levels of exosomes taken from cancer
patients are significantly increased. These vesicles taken from serum [59], as well as from
malignant tumor fluids, such as ascites fluids [60], pleural effusions [38] and urine [61]
positively correlate with the tumor progression.

Constitutive and Inducible Vesicle Secretion in Cancer and Cancer Therapy
In the tumor microenvironment, various changes are taking place, which could
have an effect on the release of vesicles, such as exosomes. Environmental changes, such
as stress induced by chemo- and radio-therapy, can modulate TEX release and the biome
they contain. This phenomenon may induce the tissues to adapt to changes taking place in
the microenvironment [62]. Tumor cells that have undergone radiation or chemotherapy
treatment have been shown to increase the release of TEX [63,64]. Interestingly, when
treated with chemotherapeutic agents, there is a significantly enhanced membrane vesicle
secretion in chemoresistant cells compared to chemosensitive cells. This activity may be
a factor leading to drug resistance [57,58]. TSAP6 is an important cellular component as
it regulates the secretion of protein via the non-classical pathway or the ER/Golgiindependent protein secretion pathway needed for the enhanced release of exosomes
[63,65,66]. Normally, the secretion of exosomes in various cell types happens at a low
rate. However, when p53 is activated, endosomal compartment activities are activated.
Simultaneously, there is an increased expression of TSAP6, inducing the release of
exosomes at a higher rate [67]. It is suggested that following p53 activation, exosomal
release may act as a ‘detoxifier’ to expel unwanted chemotherapeutic agents [5,57,58,66].
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Communication to the microenvironment is the other proposed role of TSAP6 and
exosomal release after p53 activation, which may act as a warning signal to the
neighboring cells, the immune system, and the extracellular matrix, that there are
abnormal intracellular events happening [66,67].
TEX can be used as an important biomarker for the disease, which will give
information not only on the disease progression, but on the tumor type. As previously
mentioned, TEX express specific tumor antigens which reflect the protein content of the
tumor, giving an indication of the tumor type. The content of these vesicles can also be
useful as markers for the aggressiveness of the disease.

Exosomal Survivin
Survivin is found to be localized in various subcellular locations. Depending on
its function, this IAP is shown to be in the cytoplasm, mitochondria and nucleus [23,68].
Recently, our lab has discovered that Survivin exists in the extracellular space [69],
which is released by 40-100nm membrane vesicles called exosomes [56]. Various cell
types, such as B- and T- lymphocytes, dendritic cells, neurons, intestinal epithelia cells as
well as tumor cells release exosomes [70-72]. In particular, it has been shown that both
human and mouse tumor cells release tumor cell-derived exosomes (TEX) constitutively
[37]. Additionally, specific protein content found both on and within TEX gives an
indication on not only their functional and biological roles, but also on their cell of origin,
making TEX excellent biomarkers [39,40,73]. Our lab has shown that the extracellular
pool of Survivin had the ability to cause neighboring cancer cells to become resistant to
therapy, rapidly proliferate and acquire an increased potential to become invasive [69],
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providing a protective role to the neighboring tumor cells [74]. The ability of
extracellular Survivin to cause these effects in the surrounding cancer cells comes to no
surprise as to why an overexpression of this IAP is seen in virtually every human cancer
type [21]. TEX as biomarkers can be also used as tools to detect malignant conditions.
Serum taken from cancer patients had an increased level of TEX [54,59],which had a
positive correlation with the progression of the tumor [74]. In addition to serum, TEX
was shown to be isolated from malignant tumor fluids, such as urine [61], ascites fluids
[75] and pleural effusions [38]. We have recently shown that exosomal Survivin may be a
useful tool for early detection and diagnosis or even monitoring prostate cancer
progression. Newly diagnosed and advanced Prostate cancer patients with high or lowgrade cancer had significantly higher levels of exosomal Survivin compared to control
subjects or patients with pre-inflammatory BPH [76].
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Abstract
Pancreatic cancer is a deadly and aggressive disease. Less than 1% of diagnosed
patients survive 5 years with an average survival time of only 4 - 8 months. The only
option for metastatic pancreatic cancer is chemotherapy where only the antimetabolites
gemcitabine and 5-fluorouracil are used clinically. Unfortunately, efforts to improve
chemotherapy regimens by combining, 5-fluorouracil or gemcitabine with other drugs,
such as cisplatin or oxaliplatin, have not increased cell killing or improved patient
survival. The novel antimetabolite zebularine shows promise, inducing apoptosis and
arresting cellular growth in various pancreatic cancer cell lines. However, resistance to
these antimetabolites remains a problem highlighting the need to discover and develop
new antimetabolites that will improve a patient’s overall survival.
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Introduction
In the United States, pancreatic cancer is the 4th leading cause of cancer death
aggressively and silently attacking the patient [1-3]. Pancreatic cancer is only identified
in more advanced stages when the patient is symptomatic, as there are no screening tests
for this disease [4]. At the time of diagnosis, approximately 85% of the patients have
advanced pancreatic cancer resulting is a short median survival time of 4-8 months where
less than 1% survive more than 5 years [5, 6]. Currently, the best treatment is surgical
resection where approximately 20% of patients increase their life span by approximately
2 years [7]. For metastatic pancreatic adenocarcinoma, chemotherapy using gemcitabine
(GEMZAR) is currently the only first-line FDA approved treatment [8]. Antimetabolite
drugs are designed to stop DNA replication and normal cellular metabolic processes by
different mechanisms and have been investigated for almost 70 years [9, 10]. Currently,
efforts to improve the treatment for metastatic pancreatic cancer explore using
combinations of therapeutic agents as well as searching for new antimetabolite drugs.
This review will discuss the different antimetabolite agents (Table 1) used to treat
pancreatic cancer, both clinically approved and experimental, their mechanisms of action,
and therapy resistance.

5-Fluorouracil
The pyrimidine 5-fluorouracil (5FU) has been under investigation for the
treatment of human cancers since 1954 when it was observed that uracil is utilized more
efficiently by tumor cells than normal cells [11]. The knowledge that fluorine
substitutions of hydrogen in metabolites often resulted in a toxic compound inspired the
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design of 5FU (Figure 1) and testing as a tumor-inhibiting compound [11-13]. Since its
discovery, 5FU has been used as a treatment for many solid tumors such as colon, breast,
head and neck cancers, and advanced pancreatic cancer. For 20 years, 5FU was regarded
as the only effective drug against advanced pancreatic cancer. However, despite
numerous efforts to improve therapy outcomes, the best response rate was approximately
20% [12, 14, 15].

Mechanism of Action
Like uracil, 5FU is salvaged to form 5-fluorouridine and then phosphorylated by
nucleoside and nucleotide kinases as well as reduced by ribonucleotide reductase forming
three different active metabolites (Figure 2). After incorporation of 5-fluorouridine
triphosphate (FUTP) into cellular RNA, RNA processing and post-transcriptional
modification can be inhibited [15, 16]. During DNA synthesis, 5-fluoro-2’-deoxyuridine
monophosphate (FdUMP) inhibits thymidylate synthase resulting in an imbalanced pool
of deoxynucleotide triphosphates, particularly decreased deoxythymidine triphosphate
(dTTP) and increased deoxyuridine triphosphate (dUTP). Absent dTTP, stalled DNA
polymerases can incorporate 5-fluorodeoxyuridine triphosphate (FdUTP) or dUTP which
are subsequently recognized as damaged DNA setting up a futile cycle of
misincorporation and repair [15, 16]. When DNA damage exceeds a cells ability to repair
misincorporated FdUTP or dUTP, single strand and double strand breaks accumulate
favoring cell death. Given these cellular actions of 5FU, its toxicity is generally
considered a function of transport into the cell and metabolism to active metabolites,
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Table 1. Anti-metabolite Drugs (experimental & clinical)
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Figure 1 - Structure of 5FU with the fluor group in carbon 5-position. 5FU is a
pyrimidine analog drug whose mechanism of action is through irreversible inhibition of
thymidylate synthase (TS). Clinically is have been used in the treatment of anal, breast,
colorectal, esophageal, stomach, pancreatic and skin cancers.
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Figure 2 - Mechanism of 5FU leading to RNA and DNA damage. Thymidylate synthase
inhibition is the main mechanism of action of 5FU through its active metabolite FdUMP.
Synthesis of the pyrimidine thymidine, which is required for DNA synthesis, is the result
of blocking thymidylate synthase. Thymidylate synthase methylates deoxyuridine
monophosphate (dUMP) to for thymidine monophosphate (dTMP). The use of 5FU in
cancer causes there to be a reduction leading to a scarcity of dTMP so that rapidly
dividing cancer cells die from a lack of thymine.
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particularly FdUMP, while resistance occurs when 5FU metabolism is decreased or DNA
repair is efficient.

Resistance
One mechanism of 5FU resistance may result from high levels of thymidylate
synthase expression in pancreatic cancer patients. Head and neck[17] and gastric[18]
cancer patients with low tumoral thymidylate synthase expression exhibited increased
sensitivity to 5FU treatment, while a lack of response was seen in advanced colorectal
patients[19] with high thymidylate synthase expression. Interestingly, the opposite was
observed where node-positive breast[20] and Dukes’ B and C rectal[21] cancer patients
with high expression levels of thymidylate synthase responded well to 5FU therapy. It is
not currently known why this phenomenon was seen, but 5FU therapy-outcome may be
associated with the tumor type that is being treated or with the biome of stress-associated
molecules expressed and/or induced. One retrospective study of pancreatic cancer
patients found that 5FU resulted in longer survival for patients with low thymidylate
synthase expression [22]. Further translational studies are needed to better understand the
role of thymidylate synthase expression and therapy outcome [10, 16]. These and other
studies on the mechanism of resistance continue and may prove instrumental in
understanding resistance leading to better therapeutic design and combinations.
An additional mechanism of resistance is decreased expression 5FU transport into
pancreatic cancer cells. In human pancreatic cancer cell lines, the sensitivity to 5FU
directly correlated with the expression level of the human equilibrative nucleoside
transporter 1 (hENT1) [23]. However, increased median survival time in pancreatic
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cancer patients treated with 5FU was not significantly different [24]. Additional studies
are needed to understand the differences in resistance to 5FU in cell lines as opposed to
pancreatic cancer patients.

Gemcitabine
Gemcitabine (2’, 2’-difluoro-2’deoxycytidine, dFdC) was originally considered as
an antiviral drug [25], but was later shown to demonstrate anti-cancer activity in both in
vivo and in vitro models of solid and hematological cancers [14, 25, 26]. Today,
gemcitabine is the only FDA approved single chemotherapy agent against metastatic
pancreatic cancer, showing a better 1-year survival rate, median survival, and clinical
benefit when compared to 5FU [8].

Mechanism of Action
Gemcitabine is a 2’-deoxycytidine analogue with fluorine substituted for
hydrogen at the 2’ position of the furanose ring (Figure 3). Gemcitabine is a broadspectrum agent, which has different mechanisms of action, depending upon its
phosphorylation state (Figure 4) [8, 25]. Uptake of Gem into the cell uses both human
equilibrative nucleoside transporters (hENTs) and human concentrative nucleoside
transporters (hCNTs) [27, 28]. Inside the cell, gemcitabine is phosphorylated by
deoxycytidine kinase into gemcitabine monophosphate (dFdCMP), which is further
converted into its active di- and triphosphate (dFdCDP and dFdCTP) states by nucleotide
kinases [29]. Ribonucleotide reductase is inhibited by dFdCDP leading to a reduction in
dCTP levels. Reduced dCTP lessens the negative feedback regulation of deoxycytidine
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Figure 3 - Gemcitabine is a nucleoside analog in which the hydrogen atoms on the 2’
Carbon of deoxycytidine are replaced by fluorine atoms. Like other analogues of
pyrimidines, the triphosphate analogue of gemcitabine replaces the important cytidine
building block of nucleic acids during DNA replication arresting tumor growth and
resulting in apoptosis. Gemcitabine has been used to treat various carcinomas including
lung, pancreatic, bladder and breast cancers. It is being investigated for the possible use
against esophageal cancers and lymphomas.
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Figure 4 - The broad spectrum mechanism of action of Gem, depending on its
phosphorylation state, can inhibit Riobonucleotide Reductase, Polymerase and
Deaminase activities. Once these enzymes are irreversibly inhibited, the cell cannot
produce the deoxyribonucleotides required for DNA replication and repair and the cell
dies via apoptosis.
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kinase and favors the efficient phosphorylation of gemcitabine [30]. The cytotoxic
activity of gemcitabine leading to apoptosis is mainly the result of its triphosphate form.
DNA polymerase activity is inhibited when dFdCTP is incorporated into the DNA strand
leading to a termination of the DNA chain synthesis and single strand breakage[31-33].
Consequently, a depletion of dCTP levels, due to inhibition of ribonucleotide reductase
activity, results in the competition of dFdCTP with dCTP leading to an increased
incorporation of dFdCTP into the DNA strand [30]. In addition, high intracellular levels
of dFdCTP also strongly inhibited dCMP deaminase activity, by directly inhibiting the
deaminase as well as indirectly because of the decreased dCTP:dTTP ratio [34].

Resistance
It has been shown in vitro that low levels of hENT1, leading to limited
gemcitabine intracellular uptake, is a mechanism of chemoresistance[23, 35, 36]. In
pancreatic cancer patients, the levels of hENT1 were recently observed to correlation
with overall median survival time, where patients with higher levels of hENT1 have
better survival rates[24]. Further mechanisms of resistance to gemcitabine observed in
cell lines from multiple cancer types resulted from decreases in deoxycytidine kinase
activity and increased ribonucleotide reductase activity [37]. Implications for pancreatic
cancer patients regarding activity and expression of these enzymes, however, are still
unknown [38].

Platinum
Platinum agents are used today in combination therapy regimes with gemcitabine
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as second line chemotherapy for metastatic pancreatic cancer. Cisplatin (disdiamminedichloroplatinum, CDDP, PtCl2(NH3)2) is shown in Figure 5 and is an
inorganic platinum complex composed of a doubly charged platinum ion, and four
ligands - two chloride ions and two amines. Cisplatin is a potent chemotherapy drug
discovered in the 1960’s. It is widely used today against a variety of tumors including
head and neck, non-small cell lung, stomach and bladder cancers, non-Hodgkin’s
lymphoma and sarcomas [39, 40]. Oxaliplatin (trans-l-1,2-diaminocyclohexane
oxalatoplatinum) (Figure 6) is a new platinum agent that is more potent in vitro and has a
better toxicity profile compared to cisplatin, as it only needs a small number of DNA
adducts to attain the same cytotoxicity profile as cisplatin. In preclinical studies,
oxaliplatin shows efficacy in a number of cancer cell lines, which also includes cell lines
that are cisplatin resistant [41, 42]. This provides hope that with minor modification of
these platinum compounds, not only will efficacy increase, but resistance will decrease as
well.

Mechanism of Action
Once taken up into the cells, the chloride ions are lost and replaced with water
molecules transforming cisplatin into a reactive species. Loosely bound, the water
molecules easily fall off, exposing the platinum ion which readily forms bonds with DNA
bases, forming DNA-DNA cross-links and DNA-protein cross-links. These cross-links
between bases are usually formed at sites where adenosine and guanine are adjacent on
the same DNA strand. It has been speculated that the cis-geometry of cisplatin is
important to its anti-tumor activity, as the trans-isomer of cisplatin, transplatin, is
inactive [43]. Unlike 5FU, cisplatin chemotherapy arrests cells at the G1, S or G2-M
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Figure 5 – Cisplatin has two chloride ions and two amine groups attached to the center
platinum ion. Cisplatin has been used to treat various cancers which include sarcomas
carcinomas of the lung and ovary, lymphomas and germ cell tumors and is especially
effective in treatment of testicular cancer.
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Figure 6 – Similar to Cisplatin, Oxaliplatin contains a doubly charged platinum ion in the
center. It, however, contains diamnocyclohexane and carboxylate compounds. These
platinum complexes bind to and crosslink DNA in vivo which triggers apoptosis.
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phase of the cell cycle, making this drug efficient in killing cells that are in all stages of
the cell cycle [39, 44-46].
In oxaliplatin, the two amines and two chloride ions of cisplatin are replaced with
diaminocyclohexane and carboxylate compounds, respectively (Figure 6). Similar to
cisplatin, once inside the cell, the carboxylate compound is displaced, transforming
oxaliplatin into a reactive compound that forms DNA intra-strand cross-links, DNA
interstrand cross-links, and DNA-protein cross-links [45]. DNA lesions induced by
intrastrand cross-links are formed when the drug binds to two adjacent guanine bases, and
to a lesser extent, to adjacent adenosine and guanine bases. Binding of the mismatch
repair protein complex to the DNA becomes more difficult due to the conformation of
adducts, which may result in poor repair of the lesion. Oxaliplatin has been reported to
inhibit TS activity, much like 5FU [44, 45].

Resistance
There are several mechanisms whereby tumor cells become resistant to both
cisplatin and Oxaliplatin. The toxicity of cisplatin and oxaliplatin is reduced in cells with
an efficient repair of damaged DNA where enzymes involved in nucleotide excision
repair remove the platinum-DNA adducts [39]. The relationship between enhanced
platinum resistance, a decrease in drug sensitivity, and increased DNA repair protein
levels has been described [39, 47, 48]. Another mechanism is through a decrease in
intracellular platinum concentration resulting from a reduction in drug uptake and an
increase of platinum expulsion out of the cell or detoxification by glutathione and
metallothionein and an increased level of glutathione and metallothionein has been
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shown in some cases to correlate with cisplatin resistance [49]. This resistance is not due
to only one mechanism, but on a variety of mechanisms targeting various systems [39,
44, 45]. The mechanisms of resistance for cisplatin and oxaliplatin differ from the
mechanisms of resistance for gemcitabine resulting in a benefit from combining these
agents in a therapeutic regimen.

Combination Therapy with Platinum Agents
Cisplatin and oxaliplatin are not used as single agents against pancreatic cancer,
but rather, in combination with either gemcitabine or 5FU when treatment with
gemcitabine alone has failed. There have been multiple studies on the effects of cisplatin
used in combination with gemcitabine. One phase III study showed that compared to
patients treated with gemcitabine alone, the overall median survival and progression-free
survival of patients on the Gemcitabine-cisplatin combination therapy improved, but did
not reach statistical significance [50]. Furthermore in another study, comparable results in
patients treated with Gemcitabine alone or in combination with cisplatin were observed
[46]. However, they also noted that the combination therapy was more toxic than
gemcitabine alone. Nevertheless, studies do show favor for a Gem-cisplatin combination,
where disease progression and the median 1-year event-free survival is encouraging [42].
Oxaliplatin has been used in combination with both Gemcitabine and 5FU. One study has
shown that patients with inoperable pancreatic cancer tolerated the combination of
Gemcitabine with oxaliplatin well and was recorded to be highly effective[51] while a
phase II trial showed moderate activity [41]. When in combination with 5FU, clinical
benefits were recorded and toxicity levels were acceptable [52]. These platinum agents,
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when combined with Gemcitabine or 5FU, may be a promising treatment regime for
pancreatic cancer patients.

Zebularine
Epigenetic changes accompany pancreatic tumorigenesis as well as the
acquisition of resistance to chemotherapy [53, 54]. Therapeutic agents that alter the
epigenetic state of pancreatic cancer cells are under investigation as cytotoxic agents as
well as agents to reverse acquired resistance to first-line agents. Lacking an amino group
on the C-4 position of the pyrimidine ring, zebularine ((1-β-D-Ribofuranosyl)-2(1H)pyrimidinone), a cytidine analogue (Figure 7), was originally developed as a cytidine
deaminase inhibitor. It is also a novel DNA methytransferase (DNMT) inhibitor and
unlike other DNMT inhibitors, zebularine is more stable in aqueous solution and is less
toxic in vitro and in vivo [55-57]. Continuous exposure of numerous cancer cell lines to
zebularine slowed tumor cell growth as compared to normal human fibroblast cell lines
indicating its promise as a chemotherapy agent for cancer treatment [58].

Mechanism of Action
Once inside cells, zebularine is phosphorylated by uridine-cytidine kinase.
Nucleotide kinases phosphorylate zebularine monophosphate to form zebularine
triphosphate, which is then incorporated into DNA. The 2(1H)-pyrimidinone ring is
important as its incorporation into the DNA strand leads to DNMT1 depletion and DNA
methylation inhibition. When zebularine replaces cytosine in a CpG dinucleotide and a
DNA methyltransferase attempts to methylate zebularine, an irreversible covalent
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Figure 7 – Zebularine’s structure includes a 2(1H)-pyrimidinone ring. It is a nucleoside
analog of cytidine and works by inhibiting cytidine deaminase by binding to the active
site as a covalent hydrates. It has also been shown to inhibit DNA methylation and tumor
growth in vivo and in vitro. Though entirely experimental at this time, it has been
suggested that it could be used as a chemoprevention agent or even in epigenetic therapy.
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complex is formed thus inhibiting DNA methylation [58]. In a transgenic mouse model of
breast cancer, zebularine slows tumor growth and induces cell death by both necrosis and
apoptosis [55]. Other studies show that zebularine decreases levels of DNMT1,
DNMT3a, and DNMT3b in breast cancer cell lines [59] as well as DNMT1 and partially
DNMT3b in bladder cancer cells [58]. A reduction in DNMT1 and DNMT3b was also
shown in the mammary tumors in transgenic mice [55]. The growth inhibition property of
zebularine may be due to drug incorporation into the DNA. However, the amount of
zebularine in DNA was low in normal cells and growth was minimally affected, while the
opposite was seen in cancer cells[58]. Understanding incorporation aspects of this agent
may prove useful in developing more effective analogues.

Zebularine and Pancreatic Cancer
Studies have shown that zebularine effectively slows cellular growth in CFPAC1, a pancreatic cancer cell line, by inducing the p21 and/or p16 genes [58]. The p21
protein in response to DNA damage, directly stops DNA replication and arrests cellular
growth. They have also shown a decrease in DNMT1 through the incorporation of the
2(1H)-pyrimidinone ring, as stated above [58]. In addition, studies also showed that
zebularine, as a single agent, induced apoptosis and growth arrest by inhibition of
DNMT1 in three pancreatic cancer cell lines: YAP C, DAN G and Panc-89 [60]. Though
there are minimal studies showing the potential use of zebularine in pancreatic cancer,
initial reports show promise for the use of zebularine in treating pancreatic cancer. More
studies, however, are needed to fully test the full potential of zebularine in vivo.
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Conclusion
The only effective treatment option available for patients with advanced
metastatic pancreatic adenocarcinoma remains the antimetabolite gemcitabine. Despite
efforts to improve therapy regimens by using 5FU or Gem in combination with alkylating
agents, the prognosis for treating metastatic pancreatic cancer remains bleak. Therefore, it
is imperative to continue studying and developing novel antimetabolite agents, such as
zebularine, to improve treatment options and improve overall survival rates.
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Abstract
New agent development, mechanistic understanding and combinatorial
partnerships with known and novel modalities continue to be important in the study of
pancreatic cancer and its improved treatment. In this study, known anti-metabolite drugs
such as Gemcitabine (ribonucleotide reductase inhibitor (RRI)) and 5-fluorouracil
(thymidylate synthase inhibitor (TSI)) were compared with novel members of these two
drug families in the treatment of a chemoresistant pancreatic cancer cell line PANC-1.
Cellular survival data, along with protein and mRNA expression for Survivin, XIAP,
cIAP1 and cIAP2 were compared from both the cell cytoplasm and from exosomes after
single modality treatment. While all anti-metabolite drugs killed PANC-1 cells in a timeand dose-dependent manner, neither family significantly altered the cytosolic protein
level of the four IAPs investigated. Survivin, XIAP, cIAP1 and cIAP2 were found
localized to exosomes where no significant difference in expression was recorded. This
inability for significant and long-lasting expression may be a reason why pancreatic
cancer lacks responsiveness to these and other cancer killing agents. Continued
investigation is required to determine the responsibilities of these IAPs in their role in
chemoresistance in pancreatic adenocarcinoma.

KEYWORDS: IAPs, exosomes, pancreatic cancer, antimetabolites, Gemcitabine
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Introduction
Pancreatic adenocarcinoma is the 4th leading cause of cancer death [1,2]. Out of
all diagnosed patients, only 2-5% survive 5 years, and the average survival time is only 46 months [3-6]. There are a number of treatments available for patients, but the option for
metastatic pancreatic cancer is limited to chemotherapy, of which only the antimetabolite drugs gemcitabine (Gem) and 5-fluorouracil (5FU) are clinically used [3,7,8].
Anti-metabolite drugs are designed to stop DNA synthesis and replication. Each antimetabolite differs from one another in their mechanism of actions, leading to different
cytotoxic effects. 5FU is converted into its active form FdUMP which then acts as a
thymidine synthase inhibitor. It inhibits the conversion of dUMP to dTMP by binding to
thymidine synthase and folate [9,10]. Unlike 5FU, Gem has three mechanisms of action,
making this anti-metabolite a broad-spectrum agent. Once Gem enters the cell, it is
subjected to phosphorylation by deoxycytidine kinase into gemcitabine monophosphate.
Conversion of Gem into its di- and triphosphorylation states by nucleoside kinases
converts this anti-metabolite into a ribonucleotide reductase and polymerase inhibitor,
respectively [11-13]. There have been numerous efforts to improve chemotherapy
treatment regimens by combining these chemotherapies with either 5FU or Gem in
combination. Unfortunately, most of these studies have confirmed that combination
therapy does not show significant improvements [14-16]. In addition to the failure to
improve treatment regimen, patients face the challenge of chemoresistance. Low response
rate in patients treated with Gem has been shown to be associated with innate and
acquired chemoresistance [17]. Additional studies still need to be conducted to
understand resistance to Gem and 5FU in pancreatic cancer patients.
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The inhibitor of apoptosis (IAP) family of proteins includes Survivin, XIAP,
cIAP1, and cIAP2. IAPs are characterized by a ~70 amino acid baculovirus IAP repeat
(BIR) domain and, except for Survivin, a RING domain in the C-terminus of each family
member [18,19]. XIAP directly binds to activated caspase-3, -7 and -9 using its BIR
domains, inhibiting the caspases’ function [20-23]. On the other hand, while cIAP1 and
cIAP2 are weak caspase inhibitors [24], these IAPs act as E3 ubiquitin-protein isopeptide
ligases on Smac using their RING domains to promote Smac degradation [25]. Survivin,
the smallest IAP, is both structurally and functionally unique among the rest of the IAP
family, having a multifunctional role in various cellular activities, which includes the
regulation of mitosis, protection from cell death, and adaptation to stressful environments
[26-28] . This IAP is also found to be localized in the cytoplasm, mitochondria and
nucleus, with its subcellular location determining its function [29,30]. Our lab has shown
that an extracellular pool of Survivin exists, which causes neighboring cancer cells to
become resistant to therapy, to rapidly proliferate, and acquire an increased potential to
be invasive [31].
Recently, our lab has discovered that Survivin is released by small (40-100 nm)
membrane bound vesicles called exosomes [32]. Tumor cell-derived exosomes (TEX)
have been shown to be released constitutively into the extracellular space [33], both in
vitro and in vivo [34,35]. TEX have different molecular profiles and biological roles,
giving an indication of the cell of origin [36,37]. In addition, specific protein content
found on and within TEX and exosomes in general establishes their functional role [38].
The goal of this study is to examine whether anti-metabolite treatments in PANC-1 cells
modulate IAP protein and message levels both intracellularly and exosomally. Such IAP
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modulation may indicate that these chemotherapeutic agents may contribute to
chemoresistance in pancreatic cancer cells.

Materials and Methods
Cell Cultures
The pancreatic carcinoma (PANC-1) cell line was purchased from the American
Type Culture Collection (ATCC; Manassas, VA) and maintained in DMEM (ATCC)
supplemented with 100U penicillin, 100µg/ml streptomycin, 100 µg/ml Normocin
(Invitrogen; Grand Island, NY), and 10% fetal bovine serum (FBS: CellGro; Manassas,
VA). The cells were grown in a humidified atmosphere of 37°C in 95% O2 / 5% CO2
until 60% confluent. Their conditioned medium (CM) for exosome collection was
collected after 24 hours treatment with Cladribine (CldA), Gemcitabine (Gem),
Hydroxyurea (HU), 5-Fluorodeoxyurodine (5FdU) and 5-Fluorouracil (5FU; Sigma, St.
Louis, MO). CldA, Gem, HU, 5FdU were kind gifts of Dr. Jonathan Neidigh at Loma
Linda University. All anti-metabolites were dissolved in water and various concentrations
were added to cells. For CM collection for exosome isolation, cells were plated 24 hours
prior to treatment. Media was changed before anti-metabolite treatment to ensure no
apoptotic bodies were present. PANC-1 cells were treated for 24 hours after which CM
and cells for Western blots and PCR were harvested.

Apoptosis and Cell Proliferation Analysis
Cells at 60% confluency and 37°C were treated with vehicle (water) or various
doses of anti-metabolites for 24, 48 and 72 hours. Cells were harvested and stained with
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Annexin V and PI (BioLegend; San Diego, CA) per the manufacturer’s directions.
Apoptosis and cell proliferation studies were performed and analyzed using a MACS
Quant flow cytometer and FlowJo software (Tree Star; Ashland, OR.).

Exosome Isolation
Exosomes were isolated as previously described [39] with the following
modifications. Briefly, CM was centrifuged three times prior to ultracentrifugation: 400 x
g for 10 mins to remove cells, 2,000 x g for 20 mins to remove cell debris and 10,000 x g
for 30 mins to remove nucleic acid and soluble proteins. The supernatant was collected
and stored in -80°C until needed. Exosomes were isolated from the CM by
ultracentrifugation on a 30% sucrose cushion at 100,000 x g for 16h. The exosomes in the
sucrose cushion was extracted and washed once in PBS by ultracentrifugation at 100,000
x g for 2h. The exosome pellet was resuspended in 100ul PBS or lysis buffer.
Exosomes were also isolated using ExoQuick TC™ (Systems Biosciences,
Mountain View, CA). Briefly, CM was collected from the treated cells and centrifuged at
3,000 x g for 15 mins. 2ml of ExoQuick TC™ was mixed to 10ml of CM and incubated
at 4°C overnight. Following incubation, the CM was centrifuged at 1,500 x g for 30 mins
to pellet exosomes. The exosome pellet was resuspended in the appropriate buffer and
used for RNA extraction studies.

Exosome Quantification
The amount of exosomes released was semi-quantified by assessing the
acetylcholinesterase activity, as our lab has described previously [39]. Briefly, 40µl of the
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isolated exosomes were suspended in 110µl PBS. The PBS-diluted exosome fraction was
equally divided to 3 individual wells on a 96-well flat-bottomed microplate. 1.25mM
acetylcholine and 0.1mM 5,5’-dithiobis(2-nitrobenzoic acid) were added to the exosomes
to a total volume of 300µl. The change in absorbance at 412 nm was monitored every 5
min for 30 min.
To determine total exosome number, exosomes were diluted 1:100 in PBS from
the total isolated exosome sample and analyzed using a NanoSight LM10-HS microscope
(Wiltshire, UK). Size distribution, and total number of exosomes per milliliter were
calculated by the nanoparticle tracking analysis software (Wiltshire, UK).

Western Blots
For total cell Western blot analysis, cells are harvested and lysed in cell lysis
buffer (0.5% Triton X-100, 300 mM NaCl, 50 mM Tris/HCl, 1 mM PMSF) with
sonication. The lysates were centrifuged at 10,000 rpm at 4°C for 20 mins to remove cell
debris. For exosome Western blot analysis, exosomes were solubilized in lysis buffer.
Protein concentration was determined using the BCA protein assay (Pierce Chemical;
Rockford, IL). A total of 50ug cellular protein or 40ug exosomal protein was separated
using a 7.5-12% SDS polyacrylamide gels and transferred onto nitrocellulose membrane
(BioRad; Hercules, CA). Blots were immunostained with antibodies against Survivin
((1:500-2000), NOVUS Biologicals; Littleton, CO), cIAP1, cIAP2 and XIAP ((1:5001000), Cell Signaling, Danvers, MA). β-actin ((1:1000), Cell Signaling; Danvers, MA)
was used as control for cell samples and Lamp-1 ((1:500, BioLegend, San Diego, CA)
was used as control for exosome samples. Goat anti-rabbit and anti-mouse antibodies (LI-
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COR Biosciences; Lincoln, NE) were used as secondary antibody. The immunoreactive
bands were visualized using the Odyssey imaging system (LI-COR Biosciences).

PCR
Harvested cells and isolated exosomes were resuspended in TRI Reagent®
(Molecular Research Center; Cincinnati, OH) and stored at -80°C until needed. RNA was
extracted per manufacturer’s directions. RNA quantification was performed using a
NanoDrop 2000c (Thermo Fisher Scientific; Waltham, MA). Reverse transcription of
RNA was performed using the First Strand cDNA Synthesis kit (Syd Labs, Inc.; Malden,
MA). Genomic DNA was eliminated prior to reverse transcription of RNA into cDNA. A
total concentration of 100ng/ul cDNA was utilized to perform PCR reactions using
Phusion® Flash High-Fidelity PCR Master Mix (Finnzymes, Thermo Scientific;
Pittsburgh, PA). Forward and reverse primers (IDT, San Diego, CA) have been designed
to detect Survivin, cIAP1, cIAP2 and XIAP genes (Table 1).
cDNA was amplified for detection of Survivin, cIAP1, cIAP2, XIAP and GAPDH
(housekeeping gene) using the LightCycler 1.0 system real-time thermal cycler and the
LightCycler FastStart DNA Master PLUS SYBR Green kit (Roche Applied Science). The
assessment of samples as positive for expression was based on 1) observing reproducible
cycle threshold (CT) values in two replicates of the target gene where the GAPDH
housekeeping gene showed a CT value of <30 cycles and 2) melting curve analysis
showing superimposable product in negative control samples. Gene-specific primer pairs
were designed to span introns using Roche’s Assay Design Center (www.roche-appliedscience.com). Primers were as follows: GAPDH forward, 5’-GAG TCC ACT GGC GTC
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TTC AC; GAPDH reverse, 5’-GTT CAC ACC CAT GAC GAA CA; Survivin forward,
5’-ATG GGT GCC CCG ACG TT; Survivin reverse, 5’-TCA ATC CAT GGC AGC
CAG; XIAP forward, 5’-GAC AGT ATG CAA GAT GAG TCA; XIAP reverse, 5’-GCA
AAG CTT CTC CTC TTG CAG; cIAP1 forward, 5’-AGC TAG TCT GGG ATC CAC
CTC; cIAP1 reverse, 5’-GGG GTT AGT CCT CGA TGA AG; cIAP2 forward, 5’-TGG
AAG CTA CCT CTC AGC CTA C; cIAP2 reverse, 5’-GGA ACT TCT CAT CAA CCG
AGA. Cycling parameters for all products were initial denaturation of 15 minutes at 95°C
followed by 50 cycles of 10 seconds at 95°C (denaturing), 5 seconds at 60°C (annealing),
and 15 seconds at 72°C (elongation).

Statistical Analysis
Statistical analysis was performed using a two-way analysis of variance with the
aid of GraphPad Prism statistical software (La Jolla, CA, USA), with paired t-test used
for group analysis. Densitometric analysis was conducted using our Licor Odyssey
Images (Licor, Lincoln, NE, USA). Density of individual bands was divided by β-actin,
GAPDH or LAMP-1 as the internal controls for cytosolic cellular proteins, block PCR
mRNA samples, or exosomal proteins, respectively, with each sample then divided by the
particular baseline control.

Results
Anti-metabolite Treatments Induce Growth Inhibition and Cell Death in PANC-1 Cells
CldA treatment of PANC-1 cells with various doses (50nM, 100nM, 1µM, 20µM)
showed that lower doses did not inhibit cell growth or show cytotoxic effects (Figs. 1A,
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Table 1. Forward and reverse primer dimers for IAP analysis
Survivin

cIAP1

cIAP2

XIAP

GAPDH

Forward

5'-ACCGCATCTCTACATTCAAGA-3'

Reverse

5'-TCTGTCCAGTTTCAAAAATTC-3'

Forward

5'-CACAAAACTGCCTCCCAAAGA-3'

Reverse

5'-TTAAGAGAGAAATGTACGAACAGT-3'

Forward

5'-ATGAACATAGTAGAAAACAGCATA-3'

Reverse

5'-TCATGAAAGAAATGTACGAACTGT-3'

Forward

5'-ATGACTTTTAACAGTTTTGAAGGA-'3

Reverse

5'-TTAAGACATAAAAATTTTTTGCTT-'3

Forward

5'-ACGGATTTGGTCGTATTGGGCG-3'

Reverse

5'-CTCCTGGAAGATGGTGATGG-3'
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1B). At 1µM CldA, there was a decrease in cell proliferation but no significant killing,
unlike treatment at 20µM. Treatment with Gem (1nM, 10nM, 100nM, 1µM, 10µM,
100µM) showed a time and dose dependent killing effect, while growth inhibition was
evident at all time points and doses except for 1nM (Figs. 1C, 1D). Increasing the
concentration of HU (5µM, 50µM, 100µM, 500µM, 1mM) reduced cell proliferation in a
time and dose dependent manner. However, the drug’s cytotoxic effects were only
evident with the two highest doses (Figs. 1E, 1F). Treatment with 5FdU (100pM, 1nM,
10nM, 100nM, 1µM, 10µM) (Figs. 1G, 1H) and 5FU (100nM, 500nM, 1µM, 5µM,
50µM) showed similar cytotoxic and growth inhibition profiles (Figs. 1I, 1J). Of interest,
the killing effects of the drugs were time and dose dependent, while cell proliferation was
only reduced by the higher doses at all time points (data not shown).

IAPs Expression Levels are not Reduced by Anti-metabolite Treatments and Do Not
Play a Role in Inhibiting Cell Death in PANC-1 Cells
To determine whether IAPs play a part in cell death inhibition in PANC-1 cells
and play a role in chemoresistance, sub-lethal and lethal doses were chosen to stress the
cells for 24, 48 and 72 hours. Ribonucleotide reductase inhibitors did not significantly
alter the protein expression of IAPs at 24 and 48 hours (Figs. 2A and 2B). Although not
significant, modulation of Survivin expression was shown after 72 hours, in particular
with HU treatment at 500µM
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Figure 1 - Reduction of cell proliferation in PANC-1 cells treated with
Ribonucleotide Reductase and Thymidine Synthase inhibitors. PANC-1 cells were
treated with various concentrations of Ribonucleotide Reductase inhibitors, (A, B)
Cladribine, (C, D) Gemcitabine, (E, F) Hydroxyurea, and Thymidine Synthase
Inhibitors, (G, H) 5-Fluorodeoxyurodine and (I, J) 5-Fluorouracil for different time
periods. It was evident that anti-metabolite treatment causes growth inhibition in PANC-1
cells. To determine the sublethal and lethal doses Annexin/PI assay, along with the cell
proliferation assay, was performed on cells treated with (B) Cladribine, (D) Gemcitabine,
(F) Hydroxyurea, (H) 5- Fluorodeoxyurodine and (J) 5-Fluorouracil. Cell death in
PANC-1 was a time-, and dose-dependent manner.
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Figure 2 - Modulation of IAPs after treatment of Ribonucleotide Reductase
inhibitors. Treatment with sublethal and lethal doses of Ribonucleotide Reductase
inhibitors did not decrease the levels of IAP proteins at (A) 24h, (B) 48h and (C) 72h, as
well as IAP mRNA (D) in PANC-1 cells. IAP expression was either maintained or
increased.
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(Fig. 2C). In both mRNA (Fig. 2D and S1A) and protein, IAPs expression levels were
either maintained or increased across the doses of ribonucleotide reductase inhibitors.
As shown with the ribonucleotide reductase inhibitors, treatments with thymidine
synthase inhibitors did not significantly alter IAPs protein (Figure 3A-C) or mRNA
(Figure 3D and S1A) expression levels across all time points and doses. Following the
same trend as with the other anti-metabolite family, the IAPs protein and mRNA were
either maintained or modestly increased.

Exosome Amount Released Changes with Treatment
To determine whether anti-metabolite drug-treatment stress would affect the
amount of exosomes released, an AChE assay was performed. There was no significant
difference in the amount of exosomes released in the untreated cells compared to the
treated cells (Fig. 4A). Interestingly, the BCA protein assay showed less total protein
concentration in the untreated cell sample compared to the treated cells (Fig. 4B). To
verify the results, exosomes were examined using a NanoSight LM10-HS which
determines the number of exosomes present per ml. Figure 4C shows that compared to
the untreated exosome sample, there were more exosomes present in the pooled sample
of treated exosomes.
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Figure S1 – Ribonucleotide reductase and thymidine synthase inhibitors do not
significantly affect cellular (A) or exosomal (B) levels of IAPs.
Notes: PANC-1 cells were treated for 24hours with the indicated amounts of
ribonucleotide reductase and thymidine synthase inhibitors. Cell lysates or conditioned
medium were extracted for exosomes followed by mRNA. Level of IAP mRNA was
determined by real-time polymerase chain reaction. Relative IAP to GAPDH ratios were
shown. Data are the mean ± standard deviation of three independent experiments
(*P<0.001) as compared with the control.
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Figure 3 - IAP protein and mRNA levels after treatment with Thymidine Synthase
inhibitors. Intracellular IAP protein and mRNA levels (D) were slightly modulated after
treatment with sublethal and lethal concentrations of Thymidine Synthase inhibitors at
(A) 24h, (B) 48h and (C) 72h.
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Figure 4 - Exosome release in untreated and treated cells. (A) The
acetylcholinesterase activity assay shows that there was no difference in the amount of
exosome isolated from conditioned media collected from cells that were treated with
vehicle and anti-metabolites. (B) Total exosome protein concentration taken from
isolated exosomes from untreated cells was lower compared to the treated exosomes. (C)
Total number of exosomes per ml shows that there was more exosomes present in
conditioned media taken from treated cells compared to the untreated sample.
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Protein and mRNA Inhibitor of Apoptosis Proteins Released Via Exosomes
To further investigate whether IAPs, in addition to Survivin, are released into the
extracellular space, exosomes were isolated from conditioned media taken from treated
and non-treated cells after 24 hours. Western blotting was performed to determine the
presence of IAP proteins in exosomes. As shown in Figures 5A and 5B, not only was
Survivin present in exosomes, but so were XIAP, cIAP1 and cIAP2. In addition,
treatment with anti-metabolites affected the levels of some released exosomal IAP
proteins. Treatment with ribonucleotide reductase inhibitors (Fig. 5A) decreased the
levels of exosomal cIAP2, cIAP1 and Survivin at higher concentrations while exosomal
IAPs released from cells treated with thymidine synthase inhibitors were only effective in
reducing the exosomal levels of XIAP (Fig. 5B). We next wanted to determine whether
IAP mRNAs were also present in exosomes. PCR analysis indicated that all IAPs were
present in exosomes (Fig. 5C and S1B). Surprisingly, while Survivin and cIAP1 mRNA
levels remained unchanged with treatment, the presence of cIAP2 and XIAP mRNA were
not consistent across the samples (Fig. 5C and S1B). In addition, XIAP mRNA levels
decreased in the majority of the treatments using both families of inhibitors.
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Figure 5 - Presence of IAPs protein and mRNA in exosome. Not only is Survivin
protein exported into extracellular space, but XIAP, cIAP1 and cIAP2 are also present in
exosomes. (A and B) Exosomes isolated from PANC-1 cells treated with anti-metabolites
showed a decrease of IAP protein levels. (C) IAP mRNA is found to be released
extracellularly by exosomes. Presence of cIAP2 mRNA, however, was not consistently
found in exosomes.

64

Discussion
In various types of cancer, the function and/or expression of the IAPs is not
properly regulated. This can be due to a decrease in levels of endogenous IAP inhibitors,
abnormalities in the gene or an increase in either the expression of mRNA or protein [40].
Specifically, the high levels of Survivin expression in cancer cells have been associated
with dismal prognosis, disease progression, metastatic dissemination, chemo- and
radiotherapy resistance and overall dismal disease outcome [27,41,42]. In many cancer
types such as glioblastoma, renal cell carcinoma, liver and pancreatic cancer, the
chromosome region of 11q21-23, which include both the cIAP1 and cIAP2 genes, is
shown to be amplified in these diseases, making cIAP1/2 protooncogenes. Additionally,
in about 50% of surveyed mucosa-associated lymphoid tissue (MALT) lymphoma cases,
the BIR domain of cIAP2 is fused to the C-terminus of the paracaspase mucosaassociated lymphoid tissue lymphoma translocation protein 1 (MALT1). This fusion
protein in turn constitutively activates NF-κB [40,43]. Overexpression of XIAP
correlated with poor clinical outcome, lower survival rates and aggressive tumor growth
in diffuse large B lymphoma, colorectal cancer and clear-cell renal cell carcinoma,
respectively [40]. In pancreatic adenocarcinoma specifically, it has been shown that
Survivin, XIAP, cIAP1 and cIAP2 are constitutively upregulated by NF-κB in cell lines
and tissue samples. This abnormal upregulation of IAPs also correlates with
chemotherapy resistance [44]. Numerous efforts have been made to target these IAPs to
address the problem with resistance to therapy. XIAP silencing by siRNA in pancreatic
cancer cell lines has been shown to increase Gem sensitivity [45], as well as an
enhancement of cell death when treated with both Gem and proton radiation [42]. Other
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studies have targeted Survivin showing that knocking this IAP down with siRNA caused
Gem chemosensitivity [46]. Chemotherapy treatment for metastatic pancreatic cancer is
limited and modulation of IAP protein and message levels by these anti-metabolites is yet
to be determined, both intracellularly and exosomally.
In this study, we first determined that CldA, Gem and HU were all able to
decrease cell proliferation, in addition to inducing cell death in a time and dose dependent
manner (Fig.1 A-F). We expected IAP protein and mRNA levels to be modulated by the
ribonucleotide reductase inhibitors in both sublethal and lethal doses, as cell death was
evident in these doses. Surprisingly, we observed that the IAP levels were maintained or
even increased (Fig.2). The sublethal dose of Gem was not able to decrease the levels of
IAP mRNA, but instead increased expression of all four IAPs. In addition, the lethal dose
of Gem consistently increased the levels of IAP protein across all time points.
Like the ribonucleotide reductase inhibitos, cell proliferation was decreased with
treatments of 5FdU and 5FU. Cell death was also evident in a time and dose dependent
manner (Fig.1 G-J). However, treatments with the sublethal and lethal doses also did not
reduce IAP protein and mRNA expression levels (Fig. 3). Since cell death was shown in
both sublethal and lethal doses, we expected the IAP protein and mRNA levels to be
modulated by these agents. Surprisingly, we observed that the IAP levels were
maintained or even increased. This indicates that cell death shown in Fig. 1 may not
result from a decrease of IAP levels in these cells, but is through a different mechanism.
It is thus not surprising that studies using antimetabolite compounds against leukemias
have been recently shown to overcome apoptosis resistance and trigger necroptotic cell
death [47]. Additionally, the failure to reduce the levels of IAPs intracellularly by not
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only Gem and 5FU, but by all the other agents in both antimetabolite families may play a
role in chemoresistance in pancreatic adenocarcinoma patients and why combination
therapies do not improve patient survival rates. In studies involving colon cancer cells,
cIAP2 reduction has proven to be the only means to increase the efficacy of 5FU [48,49].
Tumor exosomes have been described as “multi-purpose carriers”, having a
supportive role in the survival and growth of the tumor cells and is involved in promoting
host tissue invasion, the subsequent metastasis and facilitating immune response evasion
[50-52]. It is speculated that the diverse function of TEX is due to the various bioactive
molecules on and within the vesicles, which strongly influences the tumor
microenvironment [53-56]. We have also shown that extracellular Survivin has a
significant effect on the tumor microenvironment, causing cells to become highly
proliferative, invasive and resistant to therapy [31]. In addition to Survivin being
exosomal, we found that XIAP, cIAP1 and cIAP2 are also released into the extracellular
space via exosomes (Fig. 5).
We looked at the exosomal levels of IAP proteins treated with ribonucleotide
reductase inhibitors. We observed that the intracellular IAP expression levels did not
reflect the levels of extracellular IAP expression (Fig. 5A). Here, the levels of exosomal
IAPs were reduced, with the exception of the treatment of HU (500µM). Looking at the
exosomal IAP levels, we saw that 5FU treatments increased Survivin levels in
comparison to the other IAPs, as with the cIAP2 with 5FdU treatment at 100nM (Fig.
5B). We expected the exosomal IAP levels would reflect the IAP levels found
intracellularly. However, there were modest reductions in the exosomal IAP protein
levels in the treated samples. We hypothesize that in an attempt to compensate for
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decreasing levels of IAPs in the exosomes, chemotherapy-treated cells released more
exosomes into the extracellular space (Fig. 4 and Fig. 5). IAP mRNA were also present in
the exosomes (Figures 5C and S1B). The levels of cIAP1 and Survivin appear rather
consistent across treatment, but the inconsistent presence of XIAP and cIAP2 mRNA
may be due to truncated mRNA that is found within the exosomes. Further work in our
lab and others is still evaluating this possibility.
Taken together, the results of this study suggest that protein and mRNA IAPs are
found in exosomes and that both cellular and exosomal IAPs should be investigated for
their roles in drug resistance in pancreatic cancer. Moreover, though these
antimetabolites reduced survival and cell proliferation, levels of the four IAPs studied
here only modestly changed and at times increased in both locations depending upon the
IAP. Our findings demonstrate for the first time that IAP protein and mRNAs are found
in exosomes. More studies, however, are needed to be done in order to fully determine
the function of exosomal IAPs in the extracellular space and whether they exhibit similar
effects as extracellular Survivin. We also showed that other players are most likely
involved in the cell death of PANC-1 cells after anti-metabolite treatments, while the
failure to decrease the levels of both protein and mRNA intracellular IAPs may play a
role in chemoresistance in pancreatic cancer patients. Although Gem was not able to
reduce intracellular IAP protein and mRNA levels, Gem continues to be the first line
treatment against metastatic pancreatic cancer. The ability to have different mechanisms
of action depending on its phosphorylation state may be why Gem continues to be
superior compared to other anti-metabolites [57]. The failure to decrease the levels of
both protein and mRNA intracellular IAPs may play a role in chemoresistance in
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pancreatic cancer patients. Innate and acquired chemoresistance in patients is a
continuing problem in the clinic. Therefore, it is important to continue to find better ways
to treat pancreatic adenocarcinoma to try to overcome the problem of resistance and
improve overall patient survival rates.
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Abstract
Exosomes are endosomal-derived nanovesicles released by normal and tumor
cells which have been shown to transfer functionally active protein, lipids, mRNAs and
miRNAs between cells. Varying in molecular profiles, biological roles, functional roles
and protein contents, exosomes have been described as “multi-purpose carriers” playing a
role in supporting the survival and growth of tumor cells. The IAP Survivin has been
found to be present in tumor exosomes. However, the existence of other IAPs in tumor
exosomes is still unknown. Survivin, cIAP1, cIAP2 and XIAP mRNA and protein are
differently expressed in a panel of tumor cell lines: DLCL2, HeLa, MCF-7, PANC-1, and
PC3. Exosomes were isolated from conditioned media collected from the cells from
which RNA and protein were extracted. Our results provide evidence that like Survivin,
XIAP, cIAP1 and cIAP2 proteins are found in tumor exosomes. The mRNA expression,
however, is differentially expressed across the tumor cell lines. The presence of these
bioactive molecules in exosomes may not only serve as warning signals, but also play a
role in providing protection to the cancer cells against changes that are constantly
occurring in the tumor microenvironment.
Keywords: Exosomes, IAPs, cancer cells, tumor microenvironment
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Introduction
Exosomes are small membrane vesicles, ranging from 40-150nm in diameter, that
are shed from various cell types such as B- and T-lymphocytes, neurons, intestinal
epithelial cells, dendritic cells and tumor cells [1-3]. Tumor exosomes, which are
constitutively released into the extracellular space, have different molecular profiles,
biological roles and molecular contents, giving an indication of the cell of origin, as well
as their functional role [4-6]. Diverse tumor antigens expressed on and or in that are
secreted from neoplastic cells give an indication of the type of tumor cells from which
tumor exosomes originated [7-9]. This has also been shown in vivo, where membrane
vesicles isolated from cancer patients’ plasma and neoplastic effusions are characterized
by the expression of tumor- specific markers reflecting tumor origin [8, 10-12]. Tumor
exosomes have a role in supporting the tumor cells’ survival and growth [13]. The
specific roles include, and not limited to, evasion of host immunity [14], tissue invasion
[15] and neoangiogenesis [16, 17]. Not only do tumor exosomes contain proteins and
tumor antigens, but functional mRNA has also been shown to be contained within these
microvesicles [10].
The inhibitor of apoptosis (IAP) family of proteins are known to be endogenous
caspase inhibitors, where cIAP1, cIAP2 and XIAP directly binds to activated caspase-3, 7, -9 using their baculorvirus IAP repeat (BIR) domains [18-21]. Survivin, a unique
member of the IAP family, contains a BIR domain, but has a multifunctional role in
various cellular activities, including regulating mitosis, inhibiting cells from undergoing
apoptosis and adapting to stressful environments [22-24]. Survivin’s multifunctional role
depends on its subcellular location, where it is found to be localized in the nucleus,
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mitochondria and cytoplasm [25]. We have shown that an extracellular pool of Survivin
also exists, released from cancer cells in exosomes [26]. Upon release and resorption by
neighboring cancer cells, these cells become resistant to therapy, rapidly proliferate and
acquire an increased potential to be invasive [27]. In addition to Survivin, we also have
recently shown that cIAP1, cIAP2 and XIAP are found in exosomes collected from
PANC-1 conditioned media [28].
Here, we evaluate across a panel of cell lines representing five different cancer
types and one non-cancer, whether like Survivin, cIAP1, cIAP2 and XIAP are released
into the extracellular space via exosomes. We show that cIAP1, cIAP2 and XIAP and
Survivin protein and mRNA are released by exosomes.

Results
Intracellular IAP mRNA and Protein is Differently Expressed in Cancer Cell Lines
IAPs play an important role in the cancer cell’s ability to resist apoptosis (29). In
this study, we used five different cancer cell lines from various cancer types. All cell
lines, including a non- cancer cell line HEK293 displayed a range of IAP expression
levels at protein level (Fig. 1A). In contrast, DLCL2 expressed an increased level of
cIAP1. In comparison to protein expression, IAP mRNA is equally expressed in all the
tumor cell lines. HEK293 cells highly expressed XIAP mRNA and showed low Survivin
mRNA expression levels. In contrast, cIAP1 and cIAP2 expression levels were deficient
in HEK293 cells (Fig. 1B).
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Figure 1 - Western Blot Analysis of Survivin, cIAP1, cIAP2, XIAP and β-actin taken
from non-cancer cell line and nontreated cancer cell lines: Human embryonic kidney cell
line (HEK293), Diffuse Large Cell Cleaved (DLCL), cervical (HeLa), breast (MCF-7),
pancreatic (PANC-1), and prostate (PC3). A. Antibodies for Survivin, cIAP1, cIAP2,
XIAP and β-actin were used for Western blotting cell line-purified protein. B. mRNA
was also acquired from the same nontreated non-cancer and cancer cell lines and the
varying IAP targets were amplified using PCR. Both Western blots as well as PCR are
representative of 2-4 independent experiments.
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Amount of Exosome Released Depends on Cell Line
Tumor cells have been shown to constitutively release TEX into the extracellular
space [4]. To determine whether the type of cancer influences the amount of exosomes
released, we collected conditioned media from different cancer cell lines. The presence
and amount of purified exosomes were determined by NanoSight. Among the cancer cell
lines, HeLa, MCF-7 and PC3 released the least amount into the media (Fig. 2). To verify
that the vesicles collected were indeed exosomes, the vesicles’ mode average sizes were
analyzed using NanoSight’s nanoparticle tracking analysis software. Although a range of
vesicle sizes were detected, the majority of the collected vesicles lie within the size range
of exosomes (Fig. 3).

IAPs are Present in Exosomes
We have previously shown that Survivin, cIAP1, cIAP2 and XIAP are trafficked
into the extracellular space via exosomes [26, 28]. We therefore hypothesized that IAPs
would also be exported out of a variety of tumor cells in the same manner. We evaluated
the presence of Survivin, cIAP1, cIAP2 and XIAP from isolated exosomes collected from
conditioned media by Western blot to determine if these IAPs would be present in
exosomes. Across all cell lines, Survivin, along with cIAP1, cIAP2 and XIAP were found
in the exosomes of the cell lines evaluated (Fig. 4A). The quantity of IAPs released in the
exosomes depends on the cell line.
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Figure 2 - Histogram representing concentration of vesicles per ml to quantify exosome
numbers. Exosomal contents in conditioned medium from HEK293, DLCL2, HeLa,
MCF7, PANC-1, and PC3 cell lines. Data are the mean ±SD of 3 independent
experiments in triplicate.
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Figure 3 - Mode average size of exosomes isolated using ExoQuick TCTM. While there
were a range of sizes of vesicles isolated, the mode average size of vesicles falls in the
size range of exosomes.
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IAP mRNA are Released into the Extracellular Space by Exosomes
Exosomes serve as vesicles for not only proteins, but also for genetic materials
[30]. In addition to verifying the presence of IAP protein in the exosomes, the presence of
exosomal IAP mRNA was also investigated in the panel of tumor cell lines. To examine
this possibility, mRNA was extracted from isolated exosomes and PCR was performed.
Not all of the cancer cells showed representative abundance of all four IAPs. Survivin
mRNA was found more abundantly than all other IAPs in the cell lines evaluated (Fig.
4B).

Discussion
IAPs are characterized by an ~70 amino acid baculovirus IAP repeat (BIR)
domain and a RING domain in the C-terminus of each family member [29, 31]. IAPs are
known to be endogenous caspase inhibitors [32] directly binding to caspase-3, -7 and -9
using their BIR domains [18-21]. The IAP family regulates cell survival and members of
this family are often deregulated in cancer, which may be a factor for chemoresistance
and treatment failure [33]. In most normal adult tissues, Survivin expression is very low
or undetectable [23, 34, 35]. The high levels of Survivin expression in cancer cells have
been associated with grim prognosis, disease progression, metastatic dissemination,
therapy resistance and overall dismal disease outcome [23, 34]. The biological
characteristics of the tumor, as well as the way the host responds to the tumor also plays a
major role on the growth and spread of cancer [27]. Here we show that though there is a
consistent cellular expression of IAP mRNA in all cell lines we evaluated, there is
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Figure 4 - Western Blot Analysis of Survivin, cIAP1, cIAP2, XIAP and Lamp-1 taken
from the conditioned medium off of nontreated non-cancer and cancer cell lines: Human
embryonic kidney cell line (HEK293), Diffuse Large Cell Cleaved (DLCL), cervical
(HeLa), breast (MCF-7), pancreatic (PANC-1), and prostate (PC3). A. Antibodies for
Survivin, cIAP1, cIAP2, XIAP and Lamp-1 were used for Western blotting exosomepurified protein. B. mRNA was also acquired from the same nontreated non-cancer and
cancer cell lines and the varying IAP targets were amplified using PCR. Both Western
blots as well as PCR are representative of 2-4 independent experiments.
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a distinct cell-type specific expression of IAP protein expression (Fig. 1). IAP protein
expression varies, perhaps reflecting the cell line’s level of therapy resistance and
aggressiveness.
The tumor microenvironment is composed of a variety of cell types which make
up the invasive carcinoma, its stromal elements and the immune cells. Communication
between these components by secretion of various proteins, such as growth factors,
ECM-degrading proteinases and chemokines is crucial for the progression, development
and maintenance of the tumor [36]. Small membrane vesicles are known to be secreted
from tumors [37] and increasing interest and studies to define their role are underway to
elucidate the role of these vesicles or TEX play in cancer development and progression.
TEX have been described as “multi-purpose carriers” having vital roles in the
communication, protection, progression as well as genetic information exchange with
neighboring cells in the microenvironment [38]. Various bioactive molecules have been
found packaged within as well as on the TEX, strongly influencing the surrounding
environment [7, 39-41] through direct signaling interaction or through trafficking of these
molecules into a recipient cell(s). Survivin has a multifunctional role in various cellular
activities depending on its subcellular location. We have recently established that
Survivin is also found in the extracellular space [27] and exported out of the cancer cells
via exosomes [26]. The work described here was to establish whether other IAPs were
also exported from cancer cells in a similar fashion.
Exosomes were isolated from condition media collected from the panel of cell
lines. These samples were analyzed using the NanoSight to determine the presence and
amount of purified exosomes (Figs. 2 & 3). Release of TEX can be affected by various
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changes taking place in the microenvironment, such as chemo-, and radiation stress, as
well as the biome they contain [42-44]. Interestingly, chemoresistant cells that have been
treated with chemotherapeutic agents show a significant increase secretion of vesicles
compared to chemosensitive cells [45, 46]. The difference in the amount of exosomes
collected between cell lines could be due to stress, such as overconfluency of the cells.
Here we show that Survivin, along with cIAP1, cIAP2 and XIAP, are secreted
from tumor and non-tumor cells into the extracellular space via exosomes (Fig. 4A).
Secretion of IAPs through exosomes and their subsequent uptake by neighboring cells of
the tumor microenvironment can serve as a protective strategy from cell death. It could
also be a mechanism for these IAPs and other exosomal biomolecules to travel long
distances within the body, affecting, stabilizing or manipulating environments far from
the primary tumor in order to aid secondary tumor growth and resistance. We have shown
that Survivin, when released to the extracellular milieu has the ability to stimulate cellular
proliferation, increase resistance and invasive potential [27], and modulate immune cells
[47]. It may be that the tumor microenvironmental presence of exosome containing
biomolecules could play a bigger role in antitumor protections than the cellular
modulation of these IAPs, having significant reach beyond that possible for circulating
tumor cells.
Genetic material, found in vesicles, has been implicated in furthering tumor
growth (30). Our lab has recently shown that IAP mRNA was found in exosomes isolated
from PANC-1 conditioned media [28]. We therefore hypothesized that IAP mRNA is
also found in exosomes collected from different tumor cell lines. While Survivin mRNAs
were secreted by all the cell lines investigated in this study, cIAP2 and XIAP mRNA are
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more selectively found in the exosomes from the cell lines observed (Fig. 4B).
Interestingly, there appeared from experiment to experiment some variation in the
mRNAs found in these exosomes which was not the case with protein. We hypothesize
that this variance may be the result of the type of RNA product and its status at the time
of capture by the exosome. It may be possible that exosomes package truncated mRNAs
as their RNA transcripts undergo a widespread post-transcriptional cleavage. As a result
these truncated RNAs provide a more small RNA, regulatory role like a miRNA [48, 49].
Full length IAP mRNA transcripts were also found to be present in exosomes, which may
be translated into functional proteins upon reabsorption into recipient cells, as shown by
Skog et al [10]. In addition, the release of these bioactive molecules may not only serve
as warning signals to the neighboring cells, but also provide protection against the
constant environmental changes in the tumor microenvironment.

Materials and Methods
Cell Lines and Cultures
Cervical carcinoma (HeLa), prostate carcinoma (PC3), breast carcinoma (MCF7), pancreatic carcinoma (PANC-1) and human embryonic kidney (HEK293) cell lines
were purchased from the American Type Culture Collection (ATCC; Manassas, VA).
The non-Hodgkin’s lymphoma cell line (DLCL2) was a kind gift from Dr. Ayad Al-Katib
(Wayne State University, Detroit, MI). The cells were maintained in DMEM, McCoy’s or
RPMI (ATCC, CellGro; Manassas, VA) supplemented with 100U penicillin, 100µg/ml
streptomycin, 10% fetal bovine serum (FBS: CellGro; Manassas, VA). The cells were
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grown in a humidified atmosphere at 37°C of 95% O2 and 5% CO2 until 60% confluent
and the medium was changed. The conditioned media was collected after 24 hours.

Exosome Isolation
The method for exosome isolation was performed using ExoQuick TC™
(Mountain View, CA). Briefly, CM was collected from the treated cells and centrifuged
at 3,000 x g for 15 min. 1ml of ExoQuick TC™ was mixed with 5ml of CM and
incubated at 4°C for 12h. Following incubation, the CM was centrifuged at 1,500 x g for
30 min to pellet exosomes. The pellet was resuspended in the appropriate buffer to isolate
RNA or protein to be used for PCR or Western blot analysis. Exosome pellet resuspended
in PBS was used for NanoSight analysis.

Verification of Exosome Presence and Exosome Quantification
To verify exosome presence and determine total exosome number, exosomes
were diluted 1:10000 in PBS from the total isolated exosome sample and analyzed using
a NanoSight LM10-HS microscope (Wiltshire, UK). Size distribution and total number of
exosomes per milliliter were calculated by the nanoparticle tracking analysis software
(Wiltshire, UK).

Western Blots
For total cell Western blot analysis, the cells were harvested and lysed in cell lysis
buffer (0.5% Triton X-100, 300mM NaCl, 50mM Tris/HCl, 1mM PMSF) with
sonication. The lysates were centrifuged at 10,000 rpm at 4°C for 20 min to remove cell
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debris. For exosomes Western blot analysis, exosomes were solubilized in lysis buffer.
Protein concentration was determined using the Micro BCA protein assay (Pierce
Chemical; Rockford, IL). A total of 50µg cellular protein or 30µg exosome protein was
separated using a 10-12% SDS polyacrylamide gels and transferred onto nitrocellulose
membrane (BioRad; Hercules, CA). Blots were immunostained with antibodies against
Survivin ((1:500-2000), NOVUS Biologicals, Littleton, CO), cIAP1, cIAP2 and XIAP
((1:500-1000), Cell Signaling, Danvers, MA). β-actin ((1:1000), Cell Signaling) was used
as control for cell samples and Lamp-1 ((1:500, BioLegend, San Diego, CA) was used as
a loading control for exosome samples. Goat anti-rabbit antibodies (LI-COR Biosciences,
Lincoln, NE) were used as secondary antibody. The immunoreactive bands were
visualized using the Odyssey imaging system (LI-COR Biosciences).

PCR
Harvested cells and isolated exosomes were resuspended in TRI Reagent®
(Molecular Research Center, Cincinnati, OH) and stored at -80°C until needed. RNA was
extracted per the manufacturer’s directions. RNA quantification was performed using
NanoDrop 2000c (Thermo Fisher Scientific, Waltham, MA). Reverse transcription of
RNA was performed using the First Strand cDNA Synthesis kit (Syd Labs, Inc, Malden,
MA). Genomic DNA is eliminated prior to reverse transcription of RNA into cDNA. A
total concentration of 100ng/µl cDNA was utilized to perform PCR reactions using
Phusion® Flash High-Fidelity PCR Master Mix (Finnzymes, Thermo Scientific;
Pittsburgh, PA).The forward and reverse primers (IDT, San Diego, CA) were designed to
detect Survivin, cIAP1, cIAP2 and XIAP genes.
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CHAPTER FIVE
CONCLUSION
Pancreatic cancer remains a devastating disease. Today, the standard of care for
metastatic pancreatic adenocarcinoma is still gemcitabine monotherapy. Since 1996 when
Gem was approved to be used against pancreatic cancer, there has been no significant
advancement in the treatment for this deadly disease [1,2]. Additionally, there is a low
patient response rate to Gem due to chemoresistance, innate and acquired, which
continues to be a major problem [3]. Although Gem is the gold standard treatment,
survival of patients is extended by only 5 weeks [4]. There have been numerous efforts
and clinical trials to try to improve the efficacy of Gem in various chemotherapeutic
combinations, but to no avail [5]. In addition to improving Gem’s efficacy, the need to
develop a novel agent with a different mechanism of action, would prove move effective
in the treatment of pancreatic cancer. It is therefore important to study the different
factors of chemoresistance to aid in the discovery of new chemotherapeutic agents to
overcome this problem in the clinic.
One factor that may play a role in Gem chemoresistance is the release of bioactive
proteins into the microenvironment via TEX, such as Survivin. Within the tumor
microenvironment, constant changes are taking place such as cellular stressors by means
of chemotherapy. This may induce the cancer cells and tissues to adapt to changes, which
can modulate the release of TEX, as well as the packaging of bioactive molecules
involved in communication, protection, even exchange of genetic information between
cancer cells [6,7]. Initial observations of accelerated tumor growth in immunocompetent
and nude mice pre-treated with murine mammary TEX led to a number of studies which

97

revealed the role of TEX [8]. TEX has now been described to have a supportive role in
the survival and growth of the tumor cells and is involved in promoting host tissue
invasion, the subsequent metastasis and facilitating immune response evasion [9-11]. In
addition, exosomal Survivin has shown to cause neighboring cancer cells to proliferate
rapidly, exhibit metastatic potential and become resistant to therapy [12]. It is speculated
that the diverse function of TEX is due to the various bioactive molecules on and within
the vesicles, which strongly influences the tumor microenvironment [13-16].
We have shown that not only is Survivin released in exosomes, but also other IAP
family members, namely cIAP1, cIAP2 and XIAP. In addition to IAP proteins being
exosomal, we also discovered that IAP mRNA is present, both full length and truncated.
This phenomenon is not cell line dependent, as we have shown this to be the case in five
cancer and one non-cancer cell lines.
Cellular and exosomal IAP protein and mRNA levels in PANC-1 cells were not
decreased when treated with various anti-metabolite agents at sublethal and lethal doses.
Instead, the protein and mRNA levels remained the same or showed an increase, which
may contribute to pancreatic cancer’s lack of response to these agents and eventual
progression to chemoresistance against these anti-metabolites.
These findings can be used to design and develop novel compounds that can be
used in combination with Gem or 5FU as a combination therapy to prevent the release of
exosomal IAPs into the tumor microenvironment, decreasing proliferation rate, resistance
to therapy and potential to metastasize. As the use of Gem and 5FU in combination with
other chemotherapy agents did not show any significant benefit, the development of a
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novel therapeutic agents designed to target exosomes, in particular IAP packaging, may
make a vital impact in the treatment for metastatic pancreatic cancer.
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